Document Detail


Defining criteria for anti-mannan antibodies to protect against candidiasis.
MedLine Citation:
PMID:  15977994     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Prevention of hematogenously disseminated candidiasis and mucocutaneous disease, including Candida vaginitis, through immunological approaches is appealing for the following reason. A long-acting and safe vaccine that protects against both serotypes of Candida albicans and other important species, such as C. tropicalis and C. glabrata, should significantly reduce the incidence of various forms of candidiasis by these etiologic agents. Through extensive experimentation on protective responses in experimental animals against Candida mannan components, others and we have evidence that antibodies specific for short-chain beta-linked oligomannosides are protective against candidiasis. Although the mechanism of protection against vaginal infection requires further investigation, experimentally the ability of antibody to rapidly deposit high amounts of complement factor C3 onto the yeast cell wall is requisite for enhancing resistance against disseminated candidiasis.
Authors:
J E Cutler
Related Documents :
11493104 - Defined uv protection by apparel textiles.
11378514 - Protective autoimmunity: regulation and prospects for vaccination after brain and spina...
17922394 - A framework for assessing immunological correlates of protection in vaccine trials.
7455894 - Protection against pneumococcal bacteremia by partial splenectomy.
17612464 - Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight lati...
16545504 - Potent antigen-specific immunity to toxoplasma gondii in adjuvant-free vaccination syst...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Review    
Journal Detail:
Title:  Current molecular medicine     Volume:  5     ISSN:  1566-5240     ISO Abbreviation:  Curr. Mol. Med.     Publication Date:  2005 Jun 
Date Detail:
Created Date:  2005-06-27     Completed Date:  2005-08-25     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  101093076     Medline TA:  Curr Mol Med     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  383-92     Citation Subset:  IM    
Affiliation:
The Research Institute for Children and LSUHSC, Dept of Pediatrics and Dept of Microbiology, Children's Hospital, New Orleans, LA 70118, USA. jcutler@chnola-research.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antibodies, Fungal / blood,  immunology*
Antibodies, Monoclonal / therapeutic use*
Candida albicans / immunology,  metabolism
Candidiasis / blood,  immunology*,  prevention & control*
Cell Wall / metabolism
Complement C3 / metabolism
Female
Humans
Mannans / immunology,  therapeutic use*
Grant Support
ID/Acronym/Agency:
P01 AI061537/AI/NIAID NIH HHS; P01 AI37194/AI/NIAID NIH HHS; R01 AI24912/AI/NIAID NIH HHS
Chemical
Reg. No./Substance:
0/Antibodies, Fungal; 0/Antibodies, Monoclonal; 0/Complement C3; 0/Mannans

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  An outline of the role of anti-Candida antibodies within the context of passive immunization and pro...
Next Document:  Antifungal and antitumor activities of a monoclonal antibody directed against a stress mannoprotein ...